May 5, 2020
Athersys enrolls patients testing MultiStem cell therapy for COVID-19 induced ARDS
Athersys started enrollment of patients testing MultiStem cell therapy in a rapid advancement of clinical program for the treatment of ARDS based on prior clinical data reflecting favorable tolerability data and meaningful benefits on mortality, ventilator-free days and ICU-days